Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer

NCT02387099 is registered in ClinicalTrials.gov with GBG Forschungs GmbH as lead sponsor.

NCT NCT02387099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02387099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Tolerability of an Induction Dose Escalation of Everolimus in Patients With Metastatic Breast Cancer
Lead sponsor
GBG Forschungs GmbH
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
July 31, 2021
Enrollment
156 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, hormone receptor positive tumor